Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
In our examination of the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD), non-obese NAFLD patients without insulin resistance presented a characteristic pattern of dietary intake. Dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Namely, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Therefore, the control of dietary cholesterol intake may lead to an improvement in NAFLD, and the NPC1L1 inhibitor ezetimibe might be a promising treatment for NAFLD. We review one pathogenic aspect of lipid metabolism dysregulation in NAFLD and survey new strategies for NAFLD treatment based on the modification of cholesterol metabolism.
26 references, click to expand
-
Current and emerging therapies in nonalcoholic fatty liver disease.Semin Liver Dis. 2008 Nov;28(4):396-406 PMID: 18956296
-
Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.Int J Mol Med. 2007 Sep;20(3):351-8 PMID: 17671740
-
Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis.J Gastroenterol. 2006 Oct;41(10):971-80 PMID: 17096066
-
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.Metabolism. 2008 Dec;57(12):1711-8 PMID: 19013295
-
Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.J Biol Chem. 2005 Apr 1;280(13):12710-20 PMID: 15671032
-
Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.J Gastroenterol. 2003;38(10):954-61 PMID: 14614602
-
Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.Hepatology. 2008 Aug;48(2):474-86 PMID: 18666236
-
n-3 PUFA and lipotoxicity.Biochim Biophys Acta. 2010 Mar;1801(3):362-6 PMID: 19781663
-
The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression.Hepatol Int. 2009 Sep;3(3):490-6 PMID: 19669248
-
Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study.J Hepatol. 2008 Feb;48(2):300-7 PMID: 18086506
-
Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.Hepatology. 2007 Nov;46(5):1392-403 PMID: 17929294
-
Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.Hepatol Res. 2008;38(11):1122-9 PMID: 18684130
-
Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.Int J Mol Med. 2005 Oct;16(4):631-5 PMID: 16142397
-
Suppression of hepatic fat accumulation by highly purified eicosapentaenoic acid prevents the progression of d-galactosamine-induced hepatitis in mice fed with a high-fat/high-sucrose diet.Biochim Biophys Acta. 2009 Apr;1791(4):281-8 PMID: 19416647
-
Clinical and pathological features of non-alcoholic steatohepatitis.Hepatol Res. 2005 Oct;33(2):116-21 PMID: 16275057
-
Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.Scand J Gastroenterol. 2009;44(4):471-7 PMID: 19058085
-
Statins for hyperlipidemia in patients with chronic liver disease: are they safe?Clin Gastroenterol Hepatol. 2006 Jul;4(7):838-9 PMID: 16829348
-
A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.J Clin Gastroenterol. 2009 Nov-Dec;43(10):990-4 PMID: 19448566
-
Molecular mediators of hepatic steatosis and liver injury.J Clin Invest. 2004 Jul;114(2):147-52 PMID: 15254578
-
Recent advances in nonalcoholic fatty liver disease.Curr Opin Gastroenterol. 2009 May;25(3):230-7 PMID: 19396962
-
Lipid-lowering agents that cause drug-induced hepatotoxicity.Clin Liver Dis. 2007 Aug;11(3):597-613, vii PMID: 17723922
-
The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.Int J Mol Med. 2008 Nov;22(5):663-7 PMID: 18949388
-
SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.Int J Mol Med. 2008 Apr;21(4):507-11 PMID: 18360697
-
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.FEBS Lett. 2007 Dec 11;581(29):5664-70 PMID: 18022391
-
Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease.Int J Mol Med. 2009 May;23(5):603-8 PMID: 19360318
-
Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat.Metabolism. 2010 Apr;59(4):554-60 PMID: 19913842
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: [email protected]
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
